Targeting the cancer epigenome for therapy
Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …
Myelodysplastic syndromes
L Adès, R Itzykson, P Fenaux - The Lancet, 2014 - thelancet.com
Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by
ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid …
ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid …
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
F Morschhauser, H Tilly, A Chaidos, P McKay… - The Lancet …, 2020 - thelancet.com
Background Activating mutations of EZH2, an epigenetic regulator, are present in
approximately 20% of patients with follicular lymphoma. We investigated the activity and …
approximately 20% of patients with follicular lymphoma. We investigated the activity and …
[HTML][HTML] TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Background The molecular determinants of clinical responses to decitabine therapy in
patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are …
patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are …
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
G Garcia-Manero, EA Griffiths… - Blood, The Journal …, 2020 - ashpublications.org
This phase 2 study was designed to compare systemic decitabine exposure, demethylation
activity, and safety in the first 2 cycles with cedazuridine 100 mg/decitabine 35 mg vs …
activity, and safety in the first 2 cycles with cedazuridine 100 mg/decitabine 35 mg vs …
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
R Bejar, A Lord, K Stevenson… - Blood, The Journal …, 2014 - ashpublications.org
Only a minority of myelodysplastic syndrome (MDS) patients respond to hypomethylating
agents (HMAs), but strong predictors of response are unknown. We sequenced 40 …
agents (HMAs), but strong predictors of response are unknown. We sequenced 40 …
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Background Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype. Over
90% of tumours have lost INI1 expression, leading to oncogenic dependence on the …
90% of tumours have lost INI1 expression, leading to oncogenic dependence on the …
Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells
Epigenetic regulation of hematopoietic stem cells (HSCs) ensures lifelong production of
blood and bone marrow. Recently, we reported that loss of de novo DNA methyltransferase …
blood and bone marrow. Recently, we reported that loss of de novo DNA methyltransferase …
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
R Itzykson, O Kosmider, T Cluzeau, MD Mas, F Dreyfus… - Leukemia, 2011 - nature.com
The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA)
in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid …
in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid …
[HTML][HTML] The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation
MicroRNAs are frequently deregulated in cancer. Here we show that miR-22 is upregulated
in myelodysplastic syndrome (MDS) and leukemia and its aberrant expression correlates …
in myelodysplastic syndrome (MDS) and leukemia and its aberrant expression correlates …